BMS acquires hepatitis C compound for up to $1.1 billion
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibbis to pay ZymoGenetics up to $1.11 billion for the development and commercial rights to PEG-interferon lambda. It is a type 3 interferon currently in Phase Ib trials for the treatment of hepatitis C.